Taiwan News53m
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
62 participants with constipation predominant IBS (IBS-C) and 60 participants with diarrhoea predominant IBS (IBS-D) were dosed with EBX-102-02 or matching placebo and followed up for six weeks.
Unusual symptoms of bowel cancer as survivor issues warning after stage 4 diagnosis
Bowel cancer is becoming increasingly common in people under 50. Ellie Wilcock, was just 25 when she was diagnosed with stage ...